Last kr71.00 DKK
Change Today 0.00 / 0.00%
Volume 6.4K
ZEAL On Other Exchanges
Symbol
Exchange
Copenhagen
Berlin
OTC US
OTC US
As of 11:02 AM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

zealand pharma a/s (ZEAL) Snapshot

Open
kr71.00
Previous Close
kr71.00
Day High
kr71.00
Day Low
kr70.50
52 Week High
09/11/13 - kr79.50
52 Week Low
10/1/13 - kr55.50
Market Cap
1.6B
Average Volume 10 Days
13.1K
EPS TTM
kr-8.10
Shares Outstanding
23.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZEALAND PHARMA A/S (ZEAL)

Related News

No related news articles were found.

zealand pharma a/s (ZEAL) Related Businessweek News

No Related Businessweek News Found

zealand pharma a/s (ZEAL) Details

Zealand Pharma A/S, a biotechnology company, discovers and develops peptide drugs in Denmark. Its lead drug includes Lyxumia (lixisenatide), a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes. The company’s product pipeline also comprise Lantus and Lyxumia, which are in Phase III clinical trials for the treatment of type 2 diabetes; and ZP2929, a once-daily dual acting glucagon/GLP-1 peptide agonist that is in Phase I clinical trial for the treatment of diabetes and/or obesity. In addition, it develops danegaptide, a dipeptide gap junction modifier in Phase II clinical study with cardioprotective properties; ZP1480, an MSH melanocortin peptide agonist in Phase IIb clinical trial for the prevention of acute kidney injury following surgery; Elsiglutide, a GLP-2 peptide receptor agonist in Phase II clinical trial for the prevention of chemotherapy induced diarrhea; and ZP1848, a GLP-2 peptide agonist that has completed Phase Ib trial for the treatment of inflammatory bowel disease. Further, the company has peptide drug programs in various stages of pre-clinical development, primarily in the fields of cardio-metabolic diseases, diabetes, and obesity. Zealand Pharma A/S has collaboration agreements with Sanofi S.A.; Boehringer Ingelheim International GmbH; Helsinn Healthcare S.A.; Abbvie Inc.; and Eli Lilly. The company was founded in 1998 and is based in Copenhagen, Denmark.

111 Employees
Last Reported Date: 03/20/14
Founded in 1998

zealand pharma a/s (ZEAL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

zealand pharma a/s (ZEAL) Key Developments

Zealand Pharma A/S Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Revenue Guidance for the Year 2014

Zealand Pharma A/S reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company has posted revenue of DKK 4,294,000 against DKK 1,080,000 a year ago. Operating loss was DKK 48,112,000 against DKK 47,313,000 a year ago. Net loss for the period (after tax) was DKK 47,741,000 against DKK 46,986,000 a year ago. Diluted loss per share was DKK 2.10 against DKK 2.08 a year ago. Purchase of property, plant and equipment was DKK 353,000 against DKK 970,000 a year ago. For the six months, the company has posted revenue of DKK 89,291,000 against DKK 1,080,000 a year ago. Operating loss was DKK 19,504,000 against DKK 105,229,000 a year ago. Net loss for the period (after tax) was DKK 18,891,000 against DKK 104,313,000 a year ago. Diluted loss per share was DKK 0.83 against DKK 4.61 a year ago. Purchase of property, plant and equipment was DKK 2,036,000 against DKK 4,569,000 a year ago. For 2014, the company expects revenue from milestone payments of DKK 133 /EUR 18 million. This include DKK 81 /EUR 11 million received from Sanofi in January, DKK 37 /EUR 5 million from Boehringer Ingelheim in the third quarter and a time-based milestone from Helsinn of DKK 15 /EUR 2 million payable in the fourth quarter. Further, the company receives revenue in the form of Lyxumia(r) sales royalties, which amounted to DKK 8.1 /EUR 1.1 million for the first half of the year. No guidance can be provided for the level of royalty revenues for the full year as Sanofi has given no guidance on sales.

Zealand Pharma A/S, H1 2014 Earnings Call, Aug 21, 2014

Zealand Pharma A/S, H1 2014 Earnings Call, Aug 21, 2014

Zealand Pharma A/S Reports Sales Results for the First Half of 2014

Zealand Pharma A/S reported sales results for the first half of 2014. For the period, the company reported Lyxumia(r) royalty revenues of DKK 8.2 million based on Sanofi's global ex-US sales of the product for the period. This corresponds to an increase of 125% compared to the royalty revenue for the second half of 2013, when excluding Germany, where Sanofi, on 1 April 2014, withdrew the product from the market following the outcome of price negotiations under AMNOG law.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEAL:DC kr71.00 DKK 0.00

ZEAL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZEAL.
View Industry Companies
 

Industry Analysis

ZEAL

Industry Average

Valuation ZEAL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.3x
Price/Book 5.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZEALAND PHARMA A/S, please visit zealandpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.